Targeting TDRD9 via Hyaluronic Acid siRNA Nanoparticles: Mechanistic Insights into Neutrophil-Mediated Protection Against Pseudomonas aeruginosa Lung Injury

Study Background and Research Question

Pseudomonas aeruginosa (PA), a versatile Gram-negative bacterium, is a leading cause of hospital-acquired and opportunistic infections, particularly in immunocompromised patients. The increasing prevalence of multidrug-resistant PA strains presents a major clinical challenge, often resulting in severe pneumonia, sepsis, and high mortality rates. Neutrophils are central to early host defense against PA, but the bacterium subverts immune responses by manipulating neutrophil cell death modalities. While forms such as NETosis and pyroptosis have been studied, the role of cuproptosis—a copper-dependent regulated cell death pathway—in PA infection was unknown. This study sought to determine whether targeted gene silencing in neutrophils could therapeutically modulate this pathway, thereby alleviating lung injury during PA infection (reference study).

Key Innovation from the Reference Study

The study introduces a hyaluronic acid (HA)-coated peptide nanoparticle system for the targeted delivery of small interfering RNA (siRNA) against Tudor domain-containing protein 9 (TDRD9), a gene identified as significantly upregulated in pulmonary neutrophils during PA infection. By leveraging HA's capacity as a biopolymer for extracellular matrix mimicry and targeted delivery, the platform achieves efficient and selective siRNA transport to neutrophils. This approach not only addresses the delivery challenges of RNA therapeutics but also harnesses cell-specific immunomodulation by promoting neutrophil cuproptosis, a novel cell death pathway whose therapeutic relevance in infectious disease had not been previously established (reference).

Methods and Experimental Design Insights

The research team employed a multi-tiered approach combining transcriptomics, nanoparticle engineering, and in vivo/in vitro functional assays:

• RNA sequencing of bronchoalveolar lavage fluid-derived neutrophils from PA-infected patients and mice identified TDRD9 as a candidate gene for immune modulation.
• HA-coated peptide nanoparticles were synthesized to encapsulate siRNA targeting TDRD9, exploiting sodium hyaluronate's affinity for neutrophil surface receptors and its favorable biocompatibility as a joint lubrication biopolymer.
• Adoptive transfer experiments in neutrophil-depleted mouse models were performed to assess the functional consequences of TDRD9 silencing on pulmonary inflammation and injury.
• Mechanistic studies probed the downstream pathways, focusing on PD-L1/CD80-mediated p38 MAPK activation, a signaling cascade implicated in neutrophil survival and function.
• Human lung organoid models were used to evaluate translational relevance and the impact of nanoparticle treatment on bacterial growth, apoptosis, and inflammatory outcomes.

Core Findings and Why They Matter

Several pivotal findings emerged from the study:

• Targeted Delivery and Silencing: The HA-si-TDRD9 nanoparticles enabled efficient, selective delivery of siRNA to neutrophils, overcoming barriers of stability and cellular uptake that limit naked RNA therapies.
• Mechanistic Link to Cuproptosis: TDRD9 was shown to suppress neutrophil cuproptosis by upregulating PD-L1 via CD80-driven p38 MAPK signaling. Silencing TDRD9 reversed this suppression, promoting cuproptosis—a process characterized by copper-induced mitochondrial proteotoxic stress and loss of Fe-S-dependent enzyme activity.
• Therapeutic Efficacy in Preclinical Models: Adoptive transfer of TDRD9-silenced neutrophils into neutrophil-depleted mice significantly reduced lung inflammation, edema, and histopathological injury following PA infection. The HA-si-TDRD9 nanoparticles also decreased neutrophil accumulation in the lungs and improved overall survival.
• Reduction of Bacterial Burden and Inflammation: In human lung organoids, nanoparticle treatment led to decreased bacterial load, reduced apoptosis, and attenuated inflammatory cytokine production.

These findings establish a direct link between TDRD9-mediated signaling and neutrophil cuproptosis, positioning this pathway as a modifiable target in the context of severe bacterial pneumonia (reference study).

Comparison with Existing Internal Articles

Recent internal reviews reinforce the translational relevance of hyaluronic acid sodium salt as an extracellular matrix component in nanoparticle-based delivery systems. For example, one detailed review discusses how sodium hyaluronate's unique viscoelastic and signaling properties facilitate precision nanomedicine, supporting the mechanistic foundation for its use in the present study. Likewise, protocol-focused resources provide practical guidance on tuning HA-based nanoparticles for optimized siRNA delivery and immune targeting in infection models, aligning with the methodology described in the reference paper.

Other internal summaries, such as this article, specifically highlight the novelty of using HA-siRNA nanoparticles to enhance neutrophil cuproptosis for bacterial lung injury mitigation, thereby corroborating the study's central innovation and extending the potential for immune modulation in pneumonia therapy.

Limitations and Transferability

While the HA-si-TDRD9 nanoparticle platform demonstrates robust efficacy in preclinical models and human lung organoids, some limitations must be acknowledged:

• Species and Model Differences: Although human organoids provide translational insight, the majority of in vivo data derives from murine models, necessitating further validation in human clinical contexts.
• Potential Off-Target Effects: Even with targeted delivery, siRNA-based approaches can elicit unintended immune responses or affect genes with partial sequence homology. Careful screening and optimization are required for potential therapeutic translation.
• Heterogeneity of Neutrophil Responses: The functional diversity of neutrophils in different tissue microenvironments may influence the reproducibility and predictability of cuproptosis modulation strategies.

Despite these challenges, the study outlines a clear path for future investigation into neutrophil-targeted nanomedicine for infectious and inflammatory lung diseases.

Protocol Parameters

• HA-siRNA nanoparticle preparation: Typical sodium hyaluronate concentrations for nanoparticle coating range from 0.1–1 mg/mL; optimize based on siRNA and peptide loading, as described in the reference study.
• siRNA dosing: In vivo mouse models received 1–2 mg/kg siRNA equivalents via intravenous injection, with dosing frequency tailored to infection severity and neutrophil depletion status.
• Translational workflow tips: Employ cell-type-specific uptake assays and monitor cuproptosis markers (e.g., Fe-S enzyme loss, mitochondrial aggregation) for functional validation, as recommended in supporting protocols.
• Storage and handling: Sodium hyaluronate-based nanoparticles should be prepared fresh and stored at 4°C for short-term use; avoid repeated freeze-thaw cycles according to the product information.

Research Support Resources

Researchers aiming to replicate or extend these workflows can source Hyaluronic acid sodium salt (SKU B8382) from APExBIO for nanoparticle coating and extracellular matrix modeling. This high molecular weight shock absorption polymer is widely used in cell-based delivery and immunomodulation studies, as described in the product specifications. Proper handling and storage are essential to maintain its functional properties for advanced nanomedicine applications.